Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU
Executive Summary
Amgen’s first biosimilar – a competitor to AbbVie’s Humira – and three would-be competitors to Amgen’s own Neulasta are among the 17 biosimilar products that are under evaluation at the European Medicines Agency.
You may also be interested in...
First Biosimilar MabThera One Step Away from EU Approval; Pegfilgrastim Filings Withdrawn
The CHMP has granted a positive opinion to Celltrion’s Truxima, the first biosimilar version of Roche’s cancer treatment, MabThera, but has announced the withdrawal of two pegfilgrastim products.
Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing
Amgen and Allergan have filed an EU marketing authorization application for their biosimilar version of Roche’s monoclonal antibody product for cancer, Avastin (bevacizumab). In doing so, they join a growing number of biosimilars awaiting approval by the European authorities.
COVID-19: EU Under Pressure To Open Up On Vaccine Costs & Contracts
Transparency on COVID-19 vaccine funding, pricing and procurement is vital if vaccine hesitancy and disinformation are to be countered, say EU parliamentarians.